Aizhou Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aizhou Wang has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Marcelo Cypel
Toronto Lung Transplant Program, University Health Network, Toronto, Ontario, Canada
7 shared publications - Mingyao Liu
Institute of Medical Science, University of Toronto, Toronto, Canada; Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, Canada, Canada
6 shared publications - Shaf Keshavjee
Toronto Lung Transplant Program and Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, University of Toronto, Toronto, Ontario, Canada
6 shared publications - Aadil Ali
Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada
3 shared publications Yu Zhang
3 shared publicationsAnajara Gazzalle
Latner Thoracic Surgery Research Laboratories, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada
2 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
Harnessing Lung-Kidney Crosstalk: A Novel Ex Vivo Platform for Donor Lung Rehabilitation
- 11 November 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
Open AccessHarnessing Lung-Kidney Crosstalk: A Novel Ex Vivo Platform for Donor Lung Rehabilitation
- Open Access
- 14 October 2026
- Published by Wiley in Advanced Science
- p. e78124
Checkpoint‐Directed Glycoengineering Reprograms the Vascular Lumen for Siglec‐Mediated Immune Regulation
Dysregulated immune activation at the vascular surface drives microvascular inflammation and tissue injury in many diseases, yet current therapies do not restore immune regulation at the blood‐vessel interface. Terminal sialic acids engage inhibitory Siglec receptors on circulating immune cells and function as endogenous glyco‐immune checkpoint ligands. Loss of sialylation on vascular endothelial cells during injury disrupts this regulatory axis and promotes vascular damage. Here, we introduce a checkpoint‐directed glycoengineering strategy that installs multivalent Siglec‐engaging sialic acid ligands on a macromolecular scaffold at the vascular interface to reprogram Siglec‐mediated immune regulation. Covalent anchoring of Siglec‐engaging conjugates to the vascular surface suppressed leukocyte‐mediated cytotoxicity, inflammatory cytokine production, adhesion molecule accessibility, and complement deposition. Protection was dose‐dependent and required selective sialic acid–Siglec‐7/‐9 engagement, as demonstrated by enzymatic desialylation, Siglec‐Fc binding, and receptor blockade. In vascular allografts, this Siglec‐engaging modification preserved endothelial integrity and suppressed innate and adaptive immune activation, neutrophil recruitment, dendritic‐cell activation, and T‐cell infiltration. In an allogeneic rat kidney transplant model, this approach attenuated microvascular inflammation, complement deposition, and tissue injury, resulting in vascular protection and demonstrating the power of glycan reprogramming. These findings establish Siglec‐directed immune‐glycoengineering as a mechanistically defined local checkpoint strategy that reprograms the vasculature into an active immunoregulatory interface.
- 14 October 2026
- Published by Wiley in Advanced Science
- p. e78124
Open AccessCheckpoint‐Directed Glycoengineering Reprograms the Vascular Lumen for Siglec‐Mediated Immune Regulation
Dysregulated immune activation at the vascular surface drives microvascular inflammation and tissue injury in many diseases, yet current therapies do not restore immune regulation at the blood‐vessel interface. Terminal sialic acids engage inhibitory Siglec receptors on circulating immune cells and function as endogenous glyco‐immune checkpoint ligands. Loss of sialylation on vascular endothelial cells during injury disrupts this regulatory axis and promotes vascular damage. Here, we introduce a checkpoint‐directed glycoengineering strategy that installs multivalent Siglec‐engaging sialic acid ligands on a macromolecular scaffold at the vascular interface to reprogram Siglec‐mediated immune regulation. Covalent anchoring of Siglec‐engaging conjugates to the vascular surface suppressed leukocyte‐mediated cytotoxicity, inflammatory cytokine production, adhesion molecule accessibility, and complement deposition. Protection was dose‐dependent and required selective sialic acid–Siglec‐7/‐9 engagement, as demonstrated by enzymatic desialylation, Siglec‐Fc binding, and receptor blockade. In vascular allografts, this Siglec‐engaging modification preserved endothelial integrity and suppressed innate and adaptive immune activation, neutrophil recruitment, dendritic‐cell activation, and T‐cell infiltration. In an allogeneic rat kidney transplant model, this approach attenuated microvascular inflammation, complement deposition, and tissue injury, resulting in vascular protection and demonstrating the power of glycan reprogramming. These findings establish Siglec‐directed immune‐glycoengineering as a mechanistically defined local checkpoint strategy that reprograms the vasculature into an active immunoregulatory interface.
- Open Access
- 21 May 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (9) , 2087-2098
Metabolomic atlas of ischemia-reperfusion injury in human lung transplants: Mitochondrial stress and primary graft dysfunction
- 21 May 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (9) , 2087-2098
Open AccessMetabolomic atlas of ischemia-reperfusion injury in human lung transplants: Mitochondrial stress and primary graft dysfunction
- Open Access
- 19 March 2026
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
Itaconate supplementation leads to improvement in donor lung function after extended hypothermic preservation
- 19 March 2026
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
Open AccessItaconate supplementation leads to improvement in donor lung function after extended hypothermic preservation
- Open Access
- 17 May 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (10) , 2090-2103
Metabolic changes during cold ischemic preservation and reperfusion in porcine lung transplants
- 17 May 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (10) , 2090-2103
Open AccessMetabolic changes during cold ischemic preservation and reperfusion in porcine lung transplants
- 8 September 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (12) , 1679-1688
Evaluation of 10°C as the optimal storage temperature for aspiration-injured donor lungs in a large animal transplant model
- 8 September 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (12) , 1679-1688
Evaluation of 10°C as the optimal storage temperature for aspiration-injured donor lungs in a large animal transplant model
- 1 March 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (3) , 287-297
Ex vivo treatment of cytomegalovirus in human donor lungs using a novel chemokine-based immunotoxin
- 1 March 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (3) , 287-297
Ex vivo treatment of cytomegalovirus in human donor lungs using a novel chemokine-based immunotoxin
- Top Cited Papers
- 16 February 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (632) , eabm7190
Ex vivo enzymatic treatment converts blood type A donor lungs into universal blood type lungs
Donor organ allocation is dependent on ABO matching, restricting the opportunity for some patients to receive a life-saving transplant. The enzymes FpGalNAc deacetylase and FpGalactosaminidase, used in combination, have been described to effectively convert group A (ABO-A) red blood cells (RBCs) to group O (ABO-O). Here, we study the safety and preclinical efficacy of using these enzymes to remove A antigen (A-Ag) from human donor lungs using ex vivo lung perfusion (EVLP). First, the ability of these enzymes to remove A-Ag in organ perfusate solutions was examined on five human ABO-A1 RBC samples and three human aortae after static incubation. The enzymes removed greater than 99 and 90% A-Ag from RBCs and aortae, respectively, at concentrations as low as 1 μg/ml. Eight ABO-A1 human lungs were then treated by EVLP. Baseline analyses of A-Ag in lungs revealed expression predominantly in the endothelial and epithelial cells. EVLP of lungs with enzyme-containing perfusate removed over 97% of endothelial A-Ag within 4 hours. No treatment-related acute lung toxicity was observed. An ABO-incompatible transplant was then simulated with an ex vivo model of antibody-mediated rejection using ABO-O plasma as the surrogate for the recipient circulation using three donor lungs. The treatment of donor lungs minimized antibody binding, complement deposition, and antibody-mediated injury as compared with control lungs. These results show that depletion of donor lung A-Ag can be achieved with EVLP treatment. This strategy has the potential to expand ABO-incompatible lung transplantation and lead to improvements in fairness of organ allocation.
- 16 February 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (632) , eabm7190
Top Cited PapersEx vivo enzymatic treatment converts blood type A donor lungs into universal blood type lungs
Donor organ allocation is dependent on ABO matching, restricting the opportunity for some patients to receive a life-saving transplant. The enzymes FpGalNAc deacetylase and FpGalactosaminidase, used in combination, have been described to effectively convert group A (ABO-A) red blood cells (RBCs) to group O (ABO-O). Here, we study the safety and preclinical efficacy of using these enzymes to remove A antigen (A-Ag) from human donor lungs using ex vivo lung perfusion (EVLP). First, the ability of these enzymes to remove A-Ag in organ perfusate solutions was examined on five human ABO-A1 RBC samples and three human aortae after static incubation. The enzymes removed greater than 99 and 90% A-Ag from RBCs and aortae, respectively, at concentrations as low as 1 μg/ml. Eight ABO-A1 human lungs were then treated by EVLP. Baseline analyses of A-Ag in lungs revealed expression predominantly in the endothelial and epithelial cells. EVLP of lungs with enzyme-containing perfusate removed over 97% of endothelial A-Ag within 4 hours. No treatment-related acute lung toxicity was observed. An ABO-incompatible transplant was then simulated with an ex vivo model of antibody-mediated rejection using ABO-O plasma as the surrogate for the recipient circulation using three donor lungs. The treatment of donor lungs minimized antibody binding, complement deposition, and antibody-mediated injury as compared with control lungs. These results show that depletion of donor lung A-Ag can be achieved with EVLP treatment. This strategy has the potential to expand ABO-incompatible lung transplantation and lead to improvements in fairness of organ allocation.
- 17 October 2014
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 53 (43) , 6793-6799
Increasing Efficiency in Protein–Protein Coupling: Subunit-Directed Acetylation and Phase-Directed CuAAC (“Click Coupling”) in the Formation of Hemoglobin Bis-Tetramers
Cross-linked human hemoglobins have been evaluated for clinical use as circulating oxygen carriers. However, their induction of vasoactivity was sufficiently problematic to lead to the cessation of clinical trials. The source of vasoactivity is likely to be endothelial extravasation causing the scavenging of endogenous nitric oxide. It was recently shown that species that consist of two coupled hemoglobin tetramers do not evoke vasoactivity in a sensitive murine model. Presumably these materials are too large to extravasate. In order to make this class of material more readily available, there is a need for improved methods that can form a cross-linked bis-tetramer without producing smaller species at the same time. A potentially efficient route to cross-linking and coupling two Hb tetramers is through phase-directed copper-catalyzed azide alkyne cycloaddition (PDCuAAC). However, introduction of the necessary azide-containing cross-link gives mixtures of tetrameric and bis-tetrameric proteins, as the PDCuAAC process appears to be limited to only those proteins where the cross-link containing the azide is exclusively within the β-subunits. In order to block formation of the azide cross-link within the α-subunits, subunit-specific introduction of the azide is necessary. This is achieved by blocking reaction at the reactive amino groups of the β-subunits in the site that binds the allosteric activator 2,3-diphosphoglycerate (DPG) with inositol hexaphosphate (IHP), permitting α-selective acetylation with acetyl 3,5-dibromosalicylate. After removal of IHP, reaction with an anionic cross-linker containing an azide group occurs within the β-subunits. The resulting α-acetylated β–β′-cross-linked hemoglobin azide (acHb>-N3) undergoes efficient PDCuAAC with bis-alkynes to produce cross-linked bis-tetramers. Analysis of circular dichroism spectra of the modified species shows that there is little change in the structure of the globin chains as a result of the chemical modifications. The oxygenation properties are consistent with those needed for effective oxygenation in circulation, while the bis-tetrameric structure is sufficiently large to avoid extravasation and depletion of nitric oxide.
- 17 October 2014
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 53 (43) , 6793-6799
Increasing Efficiency in Protein–Protein Coupling: Subunit-Directed Acetylation and Phase-Directed CuAAC (“Click Coupling”) in the Formation of Hemoglobin Bis-Tetramers
Cross-linked human hemoglobins have been evaluated for clinical use as circulating oxygen carriers. However, their induction of vasoactivity was sufficiently problematic to lead to the cessation of clinical trials. The source of vasoactivity is likely to be endothelial extravasation causing the scavenging of endogenous nitric oxide. It was recently shown that species that consist of two coupled hemoglobin tetramers do not evoke vasoactivity in a sensitive murine model. Presumably these materials are too large to extravasate. In order to make this class of material more readily available, there is a need for improved methods that can form a cross-linked bis-tetramer without producing smaller species at the same time. A potentially efficient route to cross-linking and coupling two Hb tetramers is through phase-directed copper-catalyzed azide alkyne cycloaddition (PDCuAAC). However, introduction of the necessary azide-containing cross-link gives mixtures of tetrameric and bis-tetrameric proteins, as the PDCuAAC process appears to be limited to only those proteins where the cross-link containing the azide is exclusively within the β-subunits. In order to block formation of the azide cross-link within the α-subunits, subunit-specific introduction of the azide is necessary. This is achieved by blocking reaction at the reactive amino groups of the β-subunits in the site that binds the allosteric activator 2,3-diphosphoglycerate (DPG) with inositol hexaphosphate (IHP), permitting α-selective acetylation with acetyl 3,5-dibromosalicylate. After removal of IHP, reaction with an anionic cross-linker containing an azide group occurs within the β-subunits. The resulting α-acetylated β–β′-cross-linked hemoglobin azide (acHb>-N3) undergoes efficient PDCuAAC with bis-alkynes to produce cross-linked bis-tetramers. Analysis of circular dichroism spectra of the modified species shows that there is little change in the structure of the globin chains as a result of the chemical modifications. The oxygenation properties are consistent with those needed for effective oxygenation in circulation, while the bis-tetrameric structure is sufficiently large to avoid extravasation and depletion of nitric oxide.